Stem Cell Therapy for Islet Regeneration by Van, Phuc Pham
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
22 
Stem Cell Therapy 
for Islet Regeneration 
Phuc Pham Van 
University of Science, 
Vietnam National University HCM city 
Vietnam 
1. Introduction 
Diabetes mellitus is an endocrine disorder characterised by inadequate production or use of 
insulin, resulting in abnormally high blood glucose levels. High blood glucose leads to the 
formation of reactive advanced glycation end-products (Feldman et al., 1997), which are 
responsible for complications such as blindness, kidney failure, cardiovascular disease, 
stroke, neuropathy and vascular dysfunction. Diabetes mellitus is classified as either type 1 
or type 2. Type 1 diabetes mellitus (insulin-dependent diabetes mellitus) results from the 
autoimmune destruction of the pancreatic beta cells, whereas type 2 diabetes mellitus (non-
insulin-dependent diabetes mellitus) results from insulin resistance and impaired glucose 
tolerance.  
Approximately 7.8% (23.6 million people) of the US population has been diagnosed with 
diabetes mellitus, and another 57 million people are likely to develop diabetes mellitus in 
the coming years (American Diabetes Association, 2007). The number of people with 
diabetes mellitus is set to continue to rapidly increase between now and 2030, especially in 
developing countries. 
Over the last decade, a new form of treatment called islet transplantation therapy was 
thought to provide good patient outcomes; however, few islets are available for 
transplantation. Typically, the pooled islets isolated from two pancreases are enough to treat 
a single patient. Since the enormous potential of stem cells was discovered, it was hoped 
that they would provide the most effective treatment for diabetes mellitus. Over the past 
two decades, hundreds of studies have looked at the potential of stem cell therapy for 
treating diabetes mellitus. Successful stem cell therapy would eliminate the cause of the 
disease and lead to stable, long-term results; hence, the term “pancreatic regeneration” was 
coined. The hypothesis was that stem cells could regenerate the damaged pancreas. After 
careful consideration of the aetiology of diabetes mellitus, scientists have put forward two 
general treatment strategies: stem cell therapy to treat the autoimmune aspect of the disease, 
and stem cell therapy to treat the degenerative aspect of the disease. In this review, we focus 
on stem cell-based therapies aimed at islet regeneration through stem cell or insulin-
producing cell (IPC) transplantation. We will also discuss the latest strategies for treating 
both type 1 and type 2 diabetes mellitus using stem cell therapy, along with the (initially 
promising) results.  
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2. Islet regeneration by cell replacement 
2.1 Stem cell sources  
Many different types of stem cells have been used in the research, testing and treatment of 
diabetes mellitus, including stem cells that can be used to regenerate pancreatic islets, e.g. 
embryonic stem cells, adult stem cells and infant stem cells (umbilical cord stem cells 
isolated from umbilical cord blood).  
2.1.1 Embryonic stem cells  
Human embryonic stem cells (ESCs) were first isolated at the University of Wisconsin-
Madison in 1998 by James Thomson (Thomson et al., 1998). These cells were established as 
immortal pluripotent cell lines that are still in existence today. The ESCs were derived from 
blastocysts donated by couples undergoing treatment for infertility using methodology 
developed 17 years earlier to obtain mouse ESCs. Briefly, the trophectoderm is first removed 
from the blastocyst by immunosurgery and the inner cell mass is plated onto a feeder layer 
of mouse embryonic fibroblasts (Trounson et al., 2001; 2002). However, cells can also be 
derived from early human embryos at the morula stage (Strelchenko et al. 2004) after the 
removal of the zona pellucida using an acidified solution, or by enzymatic digestion by 
pronase (Verlinsky et al., 2005). Nowadays, ESCs can be isolated from many different 
sources (Fig. 1). 
ESCs are pluripotent, which means that they can differentiate into any of the functional cells 
derived from the three germ layers, including beta cells or insulin-producing cells (IPCs). 
The differentiation of ESCs into IPCs is prerequisite for their use as a diabetes mellitus 
treatment, and may occur either in vivo (after transplantation) or in vitro (before 
transplantation). In vivo differentiation is based on micro environmental conditions at the 
graft site, whereas in vitro differentiation requires various external factors that induce the 
phenotypic changes required to produce IPCs. This means that diabetes mellitus can be 
treated either by direct transplantation of ESCs, or by indirect transplantation of IPCs that 
have been differentiated from ESCs. However, Naujok et al. (2009) showed that ESCs could 
modify gene expression and exhibit a phenotype similar to that of islet cells when 
transplanted into the pancreas only if they are first differentiated in vitro, and that in vitro 
differentiation is a prerequisite for successful in vivo differentiation (Naujok et al., 2009). 
Moreover, using ESCs for pancreatic regeneration carries with it the risk of tumour 
formation after transplantation. 
Therefore, the in vitro differentiation of ESCs into IPCs is necessary before they can be used 
to treat diabetes mellitus. Studies looking at the in vitro differentiation of ESCs into IPCs 
were first performed in 2001 using mouse cells (Lumelsky et al., 2001). However, the results 
could not be repeated in subsequent studies (Rajagopal et al., 2003; Hansson et al., 2004; 
Sipione et al., 2004). Researchers then developed a strategy for selecting ESCs expressing 
genes related to pancreatic cells (e.g. nestin), and successfully generated IPCs from these 
ESCs (Soria et al., 2000; Leon-Quinto et al., 2004). Other workers succeeded in creating IPCs 
from ESCs using gene transfer (Blyszczuk et al., 2003; Schroeder et al., 2006), or 
phosphoinositol-3 kinase inhibitors (Hori et al., 2002). The differentiation of ESCs into IPCs 
usually involves  differentiation into embryoid bodies. This relatively long process 
comprises two phases: the embryoid body stage (4–5 days) and the differentiation stage (30–
40 days). In 2005, Shi et al. decreased the time taken for this differentiation process to 15 
days (Shi et al., 2005). 
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Fig. 1. ESC sources. ESCs can be isolated from fresh, frozen, dead, excess and genetically 
deficient embryos, by parthenogenesis and somatic nucleus transfer, from biopsies, and 
from pluripotent stem cells obtained from adult tissues.  
In 2001, Assady et al. reported that IPCs could be generated by spontaneous differentiation 
of human ESCs. Although the IPC number and insulin content of these cells was low, this 
was the first proof-of-principle experiment indicating that human ESCs were a potential 
source of ǃ-like cells. Recent reports from D'Amour et al. and Kroon et al. described the 
differentiation of pancreatic lineage cells from human ESCs in vitro. To date, many groups 
have reported the in vitro generation of IPCs from human ESCs (D'Amour et al., 2006; Jiang 
et al., 2007; Jiang et al., 2007).  
2.1.2 Induced pluripotent stem cells 
First created by Takahashi et al. (2007) and Yu et al. (2007), induced pluripotent stem cells 
(IPSCs) are a new source of embryonic-like stem cells, and are considered a technical 
breakthrough in stem cell research. IPSCs have several advantages over ESCs. One major 
advantage is that IPSCs can be created from any cell-type; thus, creating patient-specific 
stem cells (Park et al., 2008; Dimos et al., 2008). Similar to ESCs, IPSCs can differentiate into 
many different cell types, including neurons (Dimos et al., 2008; Chambers et al., 2008), heart 
muscle cells (Zhang et al., 2009) and insulin-secreting cells (Tateishi et al., 2008; Zhang et al., 
2009). 
IPSCs can be created from many different cell types via a simple process. First-generation 
IPSCs are obtained by transferring four genes (Oct-3/4, Sox-2, c-Myc and Klf4; Shinya 
Yamanaka et al., 2006) or Oct-3 / 4, Sox-2, Nanog and LIN28 into mice. Second-generation 
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IPSCs are derived using only Oct-3/4, Sox-2 and Klf4, because c-Myc is an oncogene 
(Nakagawa et al., 2008). Third-generation IPSCs are generated using only two genes, Oct-3/4 
and Sox-2, and the histone deacetylase inhibitor, valproic acid (VPA) (Danwei Huangfu et 
al., 2008). 
A recent study shows that IPSCs can be successfully created from adult fibroblasts derived 
from type 1 diabetic patients (Rene'Maehr et al., 2009). These cells were differentiated into 
IPCs and used to successfully treat diabetic rats (Alipio et al., 2010). 
2.1.3 Pancreatic stem cells 
A recent report by Harry Heimberg’s group (Heimberg et al., 2008) describes the existence 
of pancreatic stem cells in mice. In their most recent study, Heimberg's group ligated the 
ducts that secrete pancreatic enzymes in adult mice. The result was a doubling in the 
number of beta cells within two weeks. Also, the pancreases of the experimental animals 
began to produce more insulin; evidence that the newly generated beta cells were functional 
(Xu et al., 2008). Another research team showed that the production of new beta cells was 
dependent on the gene neurogenin 3 (Ngn3), which plays a role in the pancreas during 
embryonic development, and successfully isolated and established a murine pancreatic stem 
cell line (Noguchi et al., 2008; 2009).  
Human pancreatic stem cells have also been successfully differentiated into IPCs (Noguchi 
et al., 2010). Islet cells were isolated from the pancreases of human donors using the Ricordi 
technique modified by the Edmonton protocol. The isolated cells were then cultured in 
media specifically designed for mouse or human pancreatic embryonic stem cell culture. 
The cells were differentiated for 2 weeks in induction media containing exendin-4, 
nicotinamide, keratinocyte growth factor, PDX-1 protein, or protein BETA2/NeuroD. 
However, according to Davani et al. (2007), human islet precursor cells derived from human 
pancreases exhibit the properties of mesenchymal stem cells (MSCs) in that they adhere to 
plastic, express CD73, CD90 and CD105, and differentiate in vitro into adipocytes, 
chondrocytes, and osteocytes. Davani et al. also identified a rare population of 
CD105+/CD73+/CD90+ cells in adult human islets that express low levels of insulin mRNA 
(Davani et al., 2007). 
2.1.4 Mesenchymal stem cells 
MSCs are multipotent stem cells that can differentiate into a variety of cell types, such as 
osteoblasts (bone cells), chondrocytes (cartilage cells) and adipocytes (fat cells) (Anna et al., 
2008). This cell type was first discovered in 1924 by the cell morphologist Alexander A. 
Maximo, who described a type of cell within the mesenchyme that develops into various 
types of blood cell. Ernest A. McCulloch and James E. Till first revealed the clonal nature of 
marrow cells in 1963 (Becker et al., 1963; Siminovitch et al., 1963). Subsequently, ex vivo 
clonogenic assays were used to examine the potential of multipotent marrow cells 
(Friedenstein et al., 1974, 1976). In these assays, stromal cells or MSCs were used as colony-
forming unit-fibroblasts (CFU-f). The characteristics of MSCs are as follows: they adhere to 
culture vessels; they have a fibroblast-like shape; they express Stro-1, CD133, CD29, CD44, 
CD90, CD105 (SH2), SH3, SH4 (CD73), c-kit, CD71, and CD106; and they can differentiate 
into specialised cells, e.g. bone, cartilage and fat.  
MSCs have been isolated from many different tissues, including bone marrow (Oyajobi et 
al.. 1999; Majumdar et al., 2000; Prockop et al., 2001; Smith et al., 2004; Titorencu et al., 2007; 
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Wolfe et al., 2008; Gronthos and Zannettino et al., 2008; Phadnis et al., 2011; Bao et al., 2011), 
adipose tissue (Katz et al., 2005; Baptista et al., 2009; Caviggioli et al., 2009; Baer et al., 2010; 
Bruyn et al., 2010; Estes et al., 2010; Tucker, Bunnell, 2011), peripheral blood (Kassis et al., 
2006), umbilical cord blood (Erices et al., 2000; Rosada et al., 2003; Hutson et al., 2005; 
Reinisch et al., 2007; Bieback and Klüter et al., 2007; Perdikogianni et al., 2008; Zhang et al., 
2011), banked umbilical cord blood (Phuc et al., 2011), umbilical cords (Cutler et al., 2010; 
Farias et al., 2011), umbilical cord membranes (Deuse et al., 2010; Kita et al., 2010), umbilical 
cord veins  (Santos et al., 2010), Wharton's jelly from the umbilical cord (Zeddou  et al., 2010; 
Peng et al., 2011), placenta (Miao et al., 2006; Battula et al., 2007; Huang et al., 2009; Semenov 
et al., 2010; Pilz et al., 2011), decidua basalis (Macias et al., 2010; Lu et al., 2011), the 
ligamentum flavum (Chen et al., 2011), amniotic fluid (Feng et al., 2009; Choi et al., 2011, 
Shuang-Zhi et al., 2010), amniotic membrane (Chang et al., 2010; Marongiu et al., 2010), 
dental pulp (Agha-Hosseini et al., 2010; Karaöz et al., 2010; Yalvac et al., 2010; Spath et al., 
2010), chorionic villi from human placenta (Poloni et al., 2008), foetal membranes (Soncini et 
al., 2007), menstrual blood (Meng et al., 2007; Hida et al., 2008; Musina et al., 2008; 
Kyurkchiev et al., 2010), and breast milk (Patki et al., 2010) (Fig. 2).  
 
 
Fig. 2. Sources of MSCs. MSCs can be derived from several adult or infant tissues.  
MSCs have been successfully differentiated into IPCs in vitro and can reduce blood glucose 
levels in both animals and humans after transplantation. The in vitro differentiation of MSCs 
into IPCs requires certain substances combined with medium stress. Most successful 
protocols for the differentiation of MSCs into IPCs used nicotinamide and/or exendin-4 
inducers. Changes in the glucose concentration within the culture medium are necessary to 
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trigger this process. MSCs are commonly cultured in low glucose medium to initiate 
differentiation before they can be induced to differentiate into IPCs by nicotinamide. In 
some studies, epidermal growth factor (EGF) was added to the culture medium during the 
IPC maturation phase in addition to nicotinamide. Currently, IPCs can be generated from 
MSCs obtained from human umbilical cord blood (Gao et al., 2008; Parekh et al., 2009; Wang 
et al., 2010), banked human umbilical cord blood (Phuc et al., 2011), placenta (Kadam et al., 
2010), bone marrow (Sun et al., 2007; Xie et al., 2009; Phadnis et al., 2011), menstrual blood 
(Li et al., 2010), amniotic fluid (Trovato et al., 2009), Wharton’s jelly (Chao et al., 2008; Wu et 
al., 2009), amnion (Kadam et al., 2010), and adipose tissue (Chandra et al., 2009). Other 
studies report the successful use of transgenesis to differentiate MSCs into IPCs, or up-
regulation of genes (mainly PDX-1 or betacellulin) related to signalling pathways that trigger 
this process (Karnieli et al., 2007; Li et al., 2007; Li et al., 2008; Hisanaga et al., 2008; Limbert 
and Seufert., 2009; Yuan  et al., 2010; Paz et al., 2011). Moreover, coating the tissue culture 
flasks with substrates such as fibronectin or laminin can also induce MSCs to differentiate 
into IPCS (Moriscot et al., 2005; Chang et al., 2008; Gao et al., 2008; Lin et al., 2010; Lin et al., 
2011).  
2.1.5 Other sources 
Recent reports suggest that pancreatic duct cells, liver cells, spleen cells, and other cell types 
have the ability to differentiate into islet cells. Although it is difficult to differentiate adult 
cells into insulin-producing pancreatic cells, some researchers have shown evidence of 
pancreatic duct regeneration in mouse models. When gastrin was injected into mice to 
induce acinar cells to differentiate into duct cells, these cells became a cellular substrate for 
the formation of new beta cells, similar to the effects seen in rats receiving glucose injections 
(Weir and Bonner-Weir et al., 2004).  
Liver cells originating from the endothelium may also be candidates for this specialised 
insulin-secreting role (Meivar-Levy et al., 2006). Yang et al. (2002) reported that exposure to 
high glucose concentrations caused oval cells in the liver to differentiate into cells with a 
phenotype similar to that of pancreatic islet cells (Yang et al., 2002). Another strategy 
involves the in vivo gene transfer of the pdx-1 gene into liver cells using an adenovirus vector 
to induce endogenous pdx-1 gene expression. Pdx-1, along with other beta cell genes, is 
associated with insulin secretion (Zalzman et al., 2005; Sapir et al., 2005; Shternhall-Ron et 
al., 2007; Aviv et al., 2009; Gefen-Halevi et al., 2010; Meivar-Levy and Ferber, 2010). Similar 
to pdx-1, betacellulin and neuro-D expression by liver cells yielded sufficient insulin-
producing cells in a streptozocin (STZ)-induced diabetic mouse model. These techniques not 
only induce liver cells to differentiate into beta cells, but also create new islets within the 
liver itself (Kojima et al., 2003). Other studies showed that human foetal liver cells 
transfected with telomerase and pdx-1 can produce insulin and release it into the body. These 
cells cured diabetes mellitus when transplanted into immuno-deficient diabetic mice.  
Fibroblasts are a relatively new source of islets and are easily isolated from skin. In a recent 
study, 61 single-cell-derived dermal fibroblast clones were established from human foreskin 
using a limiting dilution technique. These cells were able to differentiate into islet-like 
clusters when induced using pancreatic-inducing medium and several hormones, including 
insulin, glucagon and somatostatin, were detectable at both the mRNA and protein levels 
after induction. Moreover, transplantation of these islet-like clusters resulted in the release 
insulin in response to glucose in vitro (Bi et al. 2010).  
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2.2 Stem cell transplantation strategies 
2.2.1 Transplantation methods 
Transplantation of stem cells/IPCs to treat diabetes mellitus has been investigated in both 
animal models and humans. Many different types of stem cells have been tested using 
different methods. Cells can be grafted underneath the kidney capsule (Rackham et al., 2011; 
Figliuzzi et al., 2009; Ito et al., 2010; Lin et al., 2009; Kodama et al., 2009; Kodama et al., 2008; 
Zhang et al., 2010; Ohmura et al., 2010; Xiao et al., 2008; Berman et al., 2010), delivered via 
intra-peritoneal injection (Boroujeni et al., 2011; Chandra et al., 2009; Koya et al., 2008; Shao 
et al., 2011; Kadam et al., 2010; Phuc et al., 2011; Lin et al., 2009) or intra-portally (Shyu et al., 
2011; Trivedi et al., 2008; Li et al., 2010; Wu et al., 2007; Longoni et al., 2010; Itakura et al., 
2007), grafted into the liver (Chao et al., 2008; Zhu et al., 2009; Xu et al., 2007; Chen et al., 
2009; Wang et al., 2010) or injected into the tail vein (Dinarvand et al., 2010; Koblas et al., 
2009; Kajiyama et al., 2010; Jurewicz et al., 2010) (Fig. 3). However, there is little research 
comparing the efficiency of these methods. Chen et al. (2009) showed that transplantation of 
stem cells into the liver produces better results than transplantation into the renal capsule. 
Although diabetes mellitus is caused by destruction of the beta cells within the pancreatic 
islets, no studies have attempted transplantation directly into the pancreas. This is because 
the pancreas is very sensitive organ and is vulnerable to mechanical intervention. 
  
 
Fig. 3. Methods of stem cell/IPC transplantation. Stem cells or IPCs can be transplanted via 
the tail vein, intraperitoneally, under the kidney capsule, into the liver, or via the portal 
vein.  
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2.2.2 Stem cell transplantation 
Unlike IPC transplantation, the mechanisms underlying islet regeneration and the 
reductions in blood glucose levels seen in diabetic patients require further study. The main 
questions that need to be answered are: 1) what role do grafted stem cells play in the 
regeneration of pancreatic islets? 2) How will stem cells behave when grafted into the body 
rather than the pancreas? 
One type of stem cell that has been used to treat diabetes mellitus and investigated 
extensively in animal models is MSCs. Almost all research on MSC transplantation shows 
that in vitro or in vivo transplantation of MSCs results in a reduction of blood glucose levels, 
weight gain and increased longevity. However, MSCs can play multiple roles. Grafted stem 
cells can move into the pancreatic islets and differentiate into IPCs (Sorvi et al., 2005; Sordi, 
2009). In an in vitro model using MSCs derived from human bone marrow and pancreatic 
islets, Sorvi et al. (2005) demonstrated crosstalk between MSCs and pancreatic cells mediated 
by various chemokines and their receptors. A minority of BM-MSCs (2–25%) express 
chemokine receptors (CXC receptor 4 [CXCR4], CX3C receptor 1 [CX3CR1], CXCR6, CC 
chemokine receptor 1 [CCR1], and CCR7) and, accordingly, show chemotactic migration in 
response to chemokine CXC ligand 12 (CXCL12), CX3CL1, CXCL16, CC chemokine ligand 3 
(CCL3), and CCL19. These factors, released from the islets, were then able to attract MSCs. 
Moreover, MSCs were detected within the pancreatic islets of mice injected with green 
fluorescent protein (GFP)-positive MSCs (Sorvi et al., 2005). This result was subsequently 
confirmed in 2009 by Sordi, who hypothesised that the crosstalk between MSCs and 
pancreatic islets was driven by the CXCR4-CXCL12 and CX3CR1-CX3CL1 axes (Sordi, 2009). 
Movement of MSCs into the pancreas after transplantation was also confirmed by Lin et al. 
(2009) and Phadnis et al. (2011). Using bone marrow-derived MSC transplantation coupled 
with down-regulation of neurogenin 3 (Ngn3) induced by a recombinant lentivirus 
encoding two different small hairpin RNAs (shRNAs) for specific interference, they showed 
the successful engraftment of MSCs. In addition, they found that the endogenous pancreatic 
stem cells differentiated into IPCs and played a major role in reversing hyperglycaemia (Lin 
et al., 2009). However, there are  cases in which stem cells derived from human umbilical 
cord blood also move into the pancreas and differentiate into IPCs in immunocompromised 
diabetic animals without improving hyperglycaemia (Koblas et al., 2009). Hasegawa et al. 
(2007) used Nos3 (-/-) mice as a model of impaired bone marrow-derived cell mobilisation 
and showed that the hyperglycaemia-improving effects of bone marrow transplantation 
were inversely correlated with the severity of myelo-suppression and delays in peripheral 
white blood cell recovery. Thus, stem cell mobilisation is critical for bone marrow 
transplantation-induced beta cell regeneration after injury. Therefore, they suggested that, 
during bone marrow transplantation, grafted cells first move into the recipient’s bone 
marrow and, subsequently, into the injured periphery to regenerate the recipient’s 
pancreatic beta cells (Hasegawa et al., 2007). 
Another study showed that MSCs display immunomodulatory functions. MSCs prevented 
beta-cell destruction and development of diabetes mellitus by inducing regulatory T cells 
(Madec et al., 2009). Thus, MSC transplantation may prevent islet cell destruction by the 
immune system seen in type 1 diabetes mellitus and the pancreatic islets can be gradually 
restored. The result was a decrease in blood sugar levels and weight gain. While in a more 
recent study, it is said that MSCs protected islets from hypoxia/reoxygenation (H/R)-
induced injury by decreasing apoptosis and increasing the expression of HIF-1ǂ, HO-1, and 
COX-2 mRNA. The MSCs induced the expression of anti-apoptotic genes, thereby 
enhancing resistance to H/R-induced apoptosis and dysfunction (Lu et al., 2010). 
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The use of ESCs for treating diabetes mellitus is limited because of high levels of tumour 
formation. So there were a few researches using the ESCs for treating diabetes mellitus. In 
one study, pancreatic cell ontogeny within ESCs transplanted into the renal capsule of STZ-
induced mice resulted in pancreatogenesis in situ or beta cell neogenesis. 
Immunohistochemistry was performed on excised pancreatic tissues using antibodies 
against stage- and lineage-specific pancreatic markers. Twenty-one days post-
transplantation, PDX-1+ pancreatic foci appeared in the renal capsule, which expressed 
exocrine enzymes (amylase) and endocrine hormones (insulin, glucagon, and somatostatin). 
These multi-hormonal endocrine cells, a characteristic of beta cell regeneration, suggested 
possible divergence from embryonic islet cell development (Kodama et al., 2008). In another 
study, Kodama et al. (2009) showed that transplanted ESCs could migrate into the injured 
pancreas. Cell tracing analysis showed that significant beta cell neogenesis occurred 2 to 3 
weeks after injury. Importantly, whereas pancreas-localised ESC or their derivatives were 
found adjacent to the sites of regeneration, neogenic pancreatic epithelia, including Ngn3+ 
cells, were endogenous. Transplantation efficiency was confirmed by enhanced endogenous 
regeneration and increased beta cell differentiation from endogenous progenitor cells 
(Kodama et al., 2009). 
2.2.3 Transplantation of differentiated stem cells 
Based on the successful transplantation of beta cells, or pancreatic islets, for the treatment of 
diabetes mellitus (Ris et al., 2011; Wahoff et al., 1995; 1996), transplantation of IPCs 
differentiated from stem cells is seen as a promising therapy for diabetic patients, particularly 
in light of the lack of tissue donors and the many side effects of insulin injections. Unlike stem 
cells, transplanted IPCs produce insulin directly. IPC transplantation using different grafting 
methods has been studied in mouse models. Routes of administration include the portal vein, 
intra-peritoneal injection, the liver, the tail vein, and the kidney capsule. IPCs, differentiated 
from bone marrow-derived MSCs, were successfully allografted into the portal vein in a rat 
model of diabetes mellitus. After transplantation, the IPCs migrated into the liver where 
they expressed islet hormones, resulting in reduced glucose levels between Days 6 and 20 
post-injection (Wu et al., 2007). Xenotransplantation of IPCs derived from fresh or banked 
human umbilical cord blood into diabetic mice also showed positive results. These IPCs, 
transplanted via the portal vein (Wang et al., 2010) or intraperitoneally (Phuc et al., 2011), 
reduced the blood glucose levels in diabetic mice. When IPCs were grafted into the portal 
vein, human C-peptides were detected in the mouse livers by immunohistochemistry (Wang 
et al., 2010). Similar to these results, xenotransplantation of IPCs differentiated from the 
Wharton’s jelly from human umbilical cords restored normoglycaemia, body weight and a 
normal glucose tolerance test, indicating that the cells are functional when grafted via the 
portal vein (Kadam et al., 2010) or liver (Chao et al., 2008).  
Zang et al. (2010) injected IPCs differentiated from human islet-derived progenitor cells 
under the renal capsule of immunodeficient mice. One month later, 19/28 mice transplanted 
with progenitor cells and 4/14 mice transplanted with IPCs produced human C-peptide that 
was detectable in the blood. This indicates that the in vivo environment further facilitates the 
maturation of progenitor cells. Moreover, 9/19 mice transplanted with progenitor cells, and 
2/4 mice transplanted with IPCs, secreted C-peptide in response to glucose (Zang et al., 
2010). Allotransplantation of IPCs differentiated from islet progenitor cells produced similar 
results (Shyu et al. 2011). In this study, progenitor cells cultured in matrigel differentiated 
into IPCs following transplantation into diabetic mice. 
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ESCs were also differentiated into IPCs and used to treat diabetes mellitus in animal models. 
After transplantation, these cells did not induce teratoma formation in STZ-induced mice 
and treatment reduced blood glucose levels to almost normal levels (Kim et al., 2003). 
Another study indicated that ESCs could differentiate into IPCs; however, transplantation of 
these pancreatic progenitor clusters into STZ-induced mice failed to reverse the 
hyperglycaemic state. This indicates that ESCs can differentiate into pancreatic progenitor 
cells and commit to a pancreatic islet cell fate, but are unable to perform the normal 
functions of beta cells (Chen et al., 2008). While most studies have focused on experimental 
treatments using IPC transplantation, another study used liver cells (rather than IPCs) to 
treat diabetes mellitus. Hepatic cells were differentiated from bone marrow-derived MSCs. 
Transplantation of syngeneic hepatic cells into STZ-induced mice cured their diabetes 
mellitus. Treatment of mice with hyperglycaemia and islet cell destruction resulted in repair 
of the pancreatic islets. Blood glucose levels, intra-peritoneal glucose tolerance tests, and 
serum insulin levels recovered significantly in the treated group. In addition, both body 
weight and the number of islets were significantly increased (Dinarvand et al., 2010).  
2.2.4 Stem cell gene therapy 
Due to their properties of self-renewal and capacity for multipotent differentiation, stem 
cells are thought to be the best vector for delivering genes and therapeutic gene-coded 
proteins into the body. Gene transfer experiments that cause stem cells to differentiate into 
beta cells, or that transfer specific genes coding for insulin, have also been conducted in 
recent years. There are several possible reasons why the use of stem cell gene therapies can 
be used to treat diabetes mellitus. However, no study has compared the difference between 
IPCs produced by chemical induction and those derived from gene transfer. Some 
researchers hypothesise that the key is the genetic transfer of the signalling pathways 
related to differentiation from stem cells into IPCs, which will create IPCs more similar to 
stem cells in vivo. Others argue that genetic modifications, e.g. PDX-1, betacellulin, or Neuro-
D transfer, induce cells to differentiate into beta cells, while yet others suggest that the 
efficiency of IPC transplantation is low because IPCs are mature, specialised cells. For long-
term effectiveness, a source of insulin with a long-term regenerative capacity is needed. 
Early studies by Xu et al. (2007), looking at transferring insulin into MSCs, showed that the 
resulting MSCs did express human insulin. The body weight of diabetic mice treated with 
these MSCs increased by 6% within 6 weeks of treatment, and average blood glucose levels 
were 10.40 +/- 2.80 mmol/l (Day 7) and 6.50 +/- 0.89 mmol/l (Day 42), compared with 
26.80 +/- 2.49 mmol/l (Day 7) and 25.40 +/- 4.10 mmol/l (Day 42) in untreated animals (p < 
0.05). Experimental diabetes mellitus was effectively relieved for up to 6 weeks after 
intrahepatic transplantation of murine MSCs expressing human insulin (Xu et al., 2007). In 
other studies, STZ-treated mice transplanted with Pdx1-transduced adipose tissue-derived 
MSCs (Pdx1-MSCs) showed significant decreases in blood glucose levels and increased 
survival compared with control mice (Lin et al., 2009; Kajiyama et al., 2010). 
2.2.5 Transplantation of immuno-isolated IPCs 
Transplantation IPCs offers a potential cell replacement therapy for patients with type 1 
diabetes mellitus. However, because of the inadequate number of cells obtained from 
donors, other stem cell sources have drawn significant attention from many research 
groups. The efficacy of these approaches is limited because they typically necessitate the 
administration of immunosuppressive agents to prevent rejection of transplanted cells. The 
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use immunosuppressive drugs can have deleterious side effects, such as increased 
susceptibility to infection, liver and kidney damage, and an increased risk of cancer. In 
addition, immunosuppressive drugs may have unexpected effects on the transplanted 
tissues. For example, some reports have shown that cyclosporine can inhibit insulin 
secretion by pancreatic cells.  
Immuno-isolation is a promising technique that protects the implanted tissues from 
rejection. One of the most common immuno-isolation techniques is to encapsulate cells 
within a semi-permeable membrane, such as alginate, that physically protects the grafts 
from the host’s immune cells while simultaneously allowing nutrients and metabolic 
products to diffuse into or out of the capsule. To achieve this, the cells are encapsulated 
within a hydrogel or alginate membrane using gravity, electrostatic forces, or coaxial airflow 
to form the capsule. Allogeneic and xenogeneic transplantation of encapsulated islets of 
Langerhans restores normal blood glucose levels in mice (Dufrane et al., 2006; Fan et al., 
1990; Omer et al., 2003), dogs (Soon-Shiong et al., 1992a,b; 1993) and non-human primates 
(Sun et al., 1996) with diabetes mellitus induced by autoimmune diseases or chemical injury, 
without on the need for immunosuppressive agents. In most of these studies, 
transplantation was via intraperitoneal injection of islet cells. However, Dufrane et al. (2006) 
recently reported the generation of encapsulated porcine islets using a Ca-alginate material. 
These capsules were implanted under the kidney capsule of nondiabetic Cynomolgus 
monkeys. The implanted porcine islets survived for up to 6 months after implantation 
without immunosuppression, even in animals injected with porcine IgG. Moreover, C-
peptide was detected in 71% of the animals. After 135 and 180 days, the explanted capsules 
still synthesised insulin and responded to glucose stimulation (Dufrane et al., 2006).  
In another study, transplantation of alginate-encapsulated IPCs from an embryo-derived 
mouse embryo progenitor-derived insulin-producing-1 (MEPI-1) cell line lowered 
hyperglycaemia in immuno-competent, allogeneic diabetic mice. After transplantation, 
hyperglycaemia was reversed and was followed by a 2.5-month period of normal to 
moderate hypoglycaemia before relapse. Relapse occurred within 2 weeks in mice 
transplanted with non-encapsulated MEPI-1 cells. Blood glucose levels, insulin levels, and 
the results of an oral glucose tolerance test all correlated directly with the number of viable 
cells remaining in the capsules in the transplanted animals (Shao et al., 2011). Moreover, 
encapsulation of IPCs differentiated from amnion-derived MSCs, or adipose tissue-derived 
MSCs in polyurethane-polyvinyl pyrrolidone macrocapsules, or IPCs in calcium alginate, 
resulted in the restoration of normoglycaemia without immunorejection (Chandra  et al., 
2009; Kadam et al., 2010) in diabetic rats  
2.2.6 Co-transplantation of stem cells and IPCs 
Allogeneic islet/IPC transplantation is an efficient method for maintaining normal glucose 
levels and for the treatment of diabetes mellitus. However, limited sources of islets/IPCs, 
high rates of islet/IPC graft failure and the need for long-term immunosuppression are 
major obstacles to the widespread application of these therapies. To overcome these 
problems, co-transplantation of pancreatic islets/IPCs and adult stem cells is considered as a 
potential target for the near future. In fact, new results suggest that co-transplantation of 
stem/precursor cells, particularly MSCs, and islets/IPCs promotes tissue engraftment and 
beta cell/IPC survival. This theory proposes that stem cells also act as "feeder" cells for the 
islets, supporting graft protection, tissue revascularisation, and immune acceptance (Sordi et 
al., 2010).  
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Overcoming the loss of islet mass is important for successful islet transplantation. Adipose 
tissue-derived stem cells (ADSCs; referred to as MSCs by some authors) have angiogenic and 
anti-inflammatory properties. Co-transplantation of ADSCs and islets into mice promotes 
survival, improves insulin secretion by the graft, and reduces the islet mass required for 
treatment (Ohmura et al., 2010). In another study, MSCs derived from adipose tissue were 
differentiated into IPCs and co-transplanted with cultured bone marrow cells into 11 diabetic 
patients (7 male, 4 female; disease duration, 1–24 years; age range, 13–43 years). Their mean 
exogenous insulin requirements were 1.14 units/kg BW/day, the mean glycosylated 
haemoglobin (Hb1Ac) level was 8.47%, and the mean c-peptide level was 0.1 ng/mL. All the 
patients received successful transplants and the mean follow-up period was 23 months. The 
results showed a decreased mean exogenous insulin requirement of 0.63 units/kgBW/day, a 
reduced Hb1Ac of 7.39%, and raised serum c-peptide levels (0.38 ng/mL). The patients 
reported no diabetic ketoacidosis events and a mean weight gain of 2.5 kg on a normal 
vegetarian diet and physical activity (Vanikar et al., 2010). However, a previous report 
indicated that similar results were obtained with undifferentiated MSC-derived adipose tissue 
co-transplanted with cultured bone marrow. In this study, human adipose tissue-derived 
MSCs were transfused along with unfractionated cultured bone marrow into five 
insulinopenic diabetic patients (2 male, 3 female; age range, 14–28 years; disease duration,  0.6 
to 10 years) being treated with human insulin (14–70 U/d). The patients had postprandial 
blood sugar levels between 156 and 470 mg%, Hb1Ac levels of 6.8% to 9.9%, and c-peptide 
levels of 0.02 to 0.2 ng/mL. After successful transplantation, all patients showed a 30% to 50% 
reduction in their insulin requirements along with a 4–26-fold increase in serum c-peptide 
levels during a mean follow-up period of 2.9 months (Trivedi  et al., 2008).  
After transplantation, MSCs appear to play an immunomodulatory role, thereby promoting 
graft acceptance. In a cynomolgus monkey model, allogeneic MSCs were co-transplanted 
with islets intra-portally on postoperative Day 0 and intravenously with donor marrow on 
postoperative Days 5 and 11. Increased co-transplantation efficiency was associated with 
increased numbers of regulatory T-cells in the peripheral blood, indicating that co-
transplantation of MSCs and islets may be an important method of enhancing islet 
engraftment and, thereby, decreasing the number of islets required (Berman et al., 2010). Co-
transplantation may also downregulate the production of pro-inflammatory cytokines. 
These results also suggest that MSCs may prevent acute rejection and improve graft 
function after portal vein pancreatic islet transplantation (Longoni et al., 2010), or that they 
may induce haematopoietic chimerism and subsequent immune tolerance without causing 
graft-versus-host disease (Itakura et al., 2007). Moreover, MSC-stimulated graft 
vascularisation and improved islet graft function are both associated with co-transplanted 
islets (Figliuzzi et al. 2009; Ito et al. 2010). In addition, interleukin (IL)-6, IL-8, vascular 
endothelial growth factor-A, hepatocyte growth factor, and transforming growth factor-beta 
were detected at significant levels in MSC culture medium. These are trophic factors 
secreted by human MSCs that enhance the survival and function of the islets after 
transplantation (Park et al., 2010).  
3. Islet regeneration by immune correction  
There is increasing evidence suggesting that both autoimmune and autoinflammatory 
mechanisms are involved in the development of type 1 and type-2 diabetes mellitus. Type 1 
diabetes mellitus is currently treated with anti-inflammatory drugs and immunosuppressive 
and immunomodulatory agents. However, despite their profound effects on immune 
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responses, these drugs do not induce clinically significant remission in certain patients. In 
recent years, stem cells have come to be regarded as the best treatment for autoimmune 
disorders, including type 1 diabetes mellitus.  
In a phase 1/2 study of autologous non-myeloablative haematopoietic stem cell (HSC) 
transplantation, C-peptide levels were detected in 23 type 1 diabetes mellitus patients (age 
range, 13–31 years). During a 7–58 month follow-up (mean, 29.8 months; median, 30 
months), 20/23 patients with no previous history of ketoacidosis and not receiving 
corticosteroids were found to be insulin free. Twelve patients maintained normal blood 
glucose levels for up to 31 months (range, 14–52 months). Eight patients suffered a relapse 
and resumed insulin injections at a lower dose (0.1–0.3 IU/kg). No mortality was reported. 
Thus, C-peptide levels increased significantly and the majority of patients achieved insulin 
independence with good glycemic control (Couri  et al., 2009).   
In another study, bone marrow from gfp transgenic mice was isolated and transplanted into 
diabetic mice. Repair of diabetic islets was evidenced by a reduction in hyperglycaemia, an 
increase in the number of islets, and altered pancreatic histology. Transplanted cells in the 
recipient pancreases expressed CD34 (an HSC marker), but not insulin, PDX-1, Ngn3, Nkx2.2, 
Nkx6.1, Pax4, Pax6, or CD45. It was concluded that BM-derived cells, especially HSCs, were 
able to repair islets by stimulating the proliferation of beta cells and the differentiation of 
pancreatic stem cells; however, they could not differentiate into beta cells or IPCs (Gao et al., 
2008). Chamson-Reig et al. (2010) used a Vav-iCre double transgenic mouse model to 
investigate the use of HSC transplantation for the treatment of type 1 diabetes mellitus. Only 
haemopoietic lineage cells expressed the Vav1 gene promoter, evidenced by expression of a 
R26R-enhanced yellow fluorescent protein (YFP) reporter gene. Between postnatal Days 2 and 
4, mice were injected with either STZ or vehicle (control). Mice were sacrificed between Days 
10 and 130 and the pancreases examined by immunofluorescence microscopy. The results 
showed that approximately 30% of YFP-positive cells within the islets co-stained for the 
endothelial cell marker, CD31. The number of haemopoietic-derived cells and the proportion 
of CD31-positive cells significantly increased 21 and 40 days after STZ treatment respectively. 
This indicates that haemopoietic lineage cells promote intra-islet angiogenesis following beta 
cell loss due to STZ treatment, which supports a partial recovery of the islets (Chamson-Reig et 
al., 2010). Huang et al. (2010) demonstrated that the role of bone marrow transplantation was 
to supply a source of very small embryonic-like cells that exist in the bone marrow without the 
need for HSCs. The authors concluded that these very small embryonic-like cells mobilise to 
the injured pancreatic tissue and contribute to beta cell regeneration after bone marrow 
transplantation (Huang et al., 2010).  
The initial results of some studies investigating the treatment of type 2 diabetes mellitus 
show that transplantation of stem cells produces good results. Intra-bone marrow-bone 
marrow transplantation plus thymus transplantation can be used to treat type 2 diabetes 
mellitus by normalising the T cell imbalance. Recipient db/db mice showed increases in body 
weight, reduced blood glucose levels, and a reduction in plasma IL-6 and IL-1ǃ levels 7 
weeks after transplantation. More importantly, treatment resulted in the restoration of 
normal CD4/CD8 ratios, increased plasma adiponectin levels, improved insulin sensitivity, 
and an increase in the number of insulin-producing cells. Furthermore, expression of 
pancreatic pAKT, pLKB1, pAMPK and HO-1 increased after transplantation. In short, this 
treatment normalises T cell subsets, and restores cytokine balance and insulin sensitivity in 
the db/db mouse model (Li et al. 2010).  
The results from some preclinical or clinical trials to treat type 1 and type 2 diabetes were 
summarized in Table 1.  
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Table 1. The results of some preclinical and clinical experiment about treating diabetes type 
1 & 2 by stem cell/IPCs transplantation. 
www.intechopen.com
 
Stem Cell Therapy for Islet Regeneration 
 
565 
4. Conclusion 
Taking into account all the currently available results (Table 1), we can expect that diabetes 
mellitus will be successfully treated using stem cell therapy in the near future. However, 
questions regarding the survival of the cells after grafting and improvements in the vitality 
and maintenance of cellular function after transplantation remain to be answered. On the 
basis of evidence supporting the many advantages of bone marrow transplantation, 
umbilical cord blood transplantation, and HSC therapy for blood-related diseases, the 
strategy of HSC/BM/UCB may produce several positive results in the coming years and 
become the treatment of choice for both type 1 and type 2 diabetes mellitus. Although more 
difficult, ESCs or adult stem cell-derived IPC transplantation are also important treatments 
for diabetes mellitus, especially when HSCs are in short supply. 
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